Renal Cell Carcinoma: The Translation of Molecular Biology Into New Treatments, New Patient Outcomes, and Nursing Implications
Nancy P. Moldawer, RN, MSN, and Robert Figlin, MD, FACP Purpose/Objectives: To provide an overview of the current knowledge and treatment options for renal cell carcinoma (RCC).
Data Sources: Published articles, published abstracts, online databases, and package inserts.
Data Synthesis: Researchers have an increased understanding of the genetic and prognostic risk factors associated with RCC. Most patients with this rare type of cancer have or will develop metastasis. Nephrectomy treats localized disease and cytokine therapy was the previous standard for metastatic disease, but newly approved targeted agents, such as sorafenib, temsirolimus, and sunitinib, as well as investigational agents such as bevacizumab, are improving patient outcomes.
Conclusions: Understanding the biologic basis of RCC has led to therapies that are transforming the goals for treatment outcomes in patients with metastatic disease and increasing time to progression with manageable side effects. Better understanding of tumor biology has led to new techniques for staging patients, new treatment approaches, and more sophisticated ways to assess patient quality of life, each of which will have an effect on nursing practice, particularly on patient counseling and management of treatment-related side effects. This review will examine the epidemiology, pathogenesis, diagnosis, and staging of rcc, with a brief discussion of developments in treatment and a range of nursing interventions that are appropriate for supporting patients with rcc and their families and caregivers.
